CYP19A1 and breast carcinoma: The study demonstrated a reduction in bone resorption rates with EPA/DHA supplementation (4 g/day) in 38 postmenopausal breast cancer survivors on aromatase inhibitors (p < 0.05), suggesting potential protection against treatment-induced bone loss.